You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Ariad stock up sharply for second straight day

Ariad Pharmaceuticals Inc. stock climbed sharply for the second consecutive day Friday on market speculation that the Cambridge biotechnology company is a takeover target.

Shares of Ariad closed up $1.47 to $8.99, gaining 19.5 percent on the Nasdaq exchange even as the broader markets tumbled. Ariad’s strong push followed a 12.07 percent stock gain on Thursday.

Continue reading below

Traders were reacting to a report by the Mail, a British news website, that three global pharmaceutical giants — Eli Lilly and Co., GlaxoSmithKline PLC, and Shire PLC — had made overtures to Ariad about acquiring the company. None of the drug makers would comment.

Ariad resumed selling its leukemia drug Iclusig in the United States last week after suspending sales in October when the Food and Drug Administration issued a safety alert. Under an agreement between Ariad and the FDA, the treatment is being sold only to a narrow segment of patients — those for whom there are no other effective treatments.

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of